ASAN

Asana

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Technology

industry

Software - Application

Exchange

NYSE

County of HQ

United States

Next Earnings Date

06/02/26

Business Summary

DaVita operates outpatient medical care facilities focused on specialized treatment delivery, generating revenue through recurring patient treatments reimbursed by insurers and government programs. The business model is scale-driven: fixed clinical infrastructure and staffing are leveraged across a steady patient base, creating operating leverage when utilization is optimized. Its moat stems from geographic density, payer relationships, regulatory complexity, and high switching costs for patients requiring continuous care. Cash generation depends on disciplined cost control, reimbursement rate management, and maximizing throughput across its treatment network.

VALUATION

P/E

-

Market Cap ($M USD)

$1,299

Forward P/E

11.9

PEG

-

PRICE TO SALES

1.6

PRICE TO BOOK

8.4

EV / EBITDA

-7

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.80

Next Year EPS Growth Estimate

$0.46

Next Year Revenue Growth Estimate

7.80%

Return on Equity (ROE)

-122.60%

Operating Margin

-24.90%

Debt-to-Equity

1.6

Piotroski F-Score

5

Altman Z-Score

-2.1

Return on Invested Capital (ROIC)

-44.00%%

Current Ratio

1.2

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At 15.8x earnings and just 9.2x forward earnings with a PEG of 0.9, the market is pricing DVA as a low-growth, balance-sheet-risked operator rather than a compounding healthcare platform. The forward multiple discount relative to the current P/E implies earnings expansion toward the $9.72 EPS estimate, suggesting upside if execution holds. However, an Altman Z-Score of 1.6 places the company in financial distress territory, meaning equity holders are being compensated with a compressed multiple for elevated solvency risk. This is a statistically cheap stock, but it is cheap because the balance sheet and margin structure demand a risk premium.

AI Exposure / Tech Reliance

As a Medical Care Facilities operator, DVA sits in a labor- and infrastructure-heavy segment where AI will likely drive incremental efficiency rather than disruptive displacement. Automation in patient scheduling, billing optimization, and clinical workflow could improve cost control in an industry facing margin pressure. The company’s ability to leverage technology will determine whether its negative operating margin can structurally improve over time.

The Bull Case

A value or GARP investor buys this because the earnings engine is intact despite market skepticism. ROIC of 10.90% against a 9.2 forward P/E signals the company still earns solid returns on invested capital relative to its valuation. A Piotroski F-Score of 6 indicates fundamentally stable operations rather than deterioration, and projected EPS growth to $9.72 alongside a PEG of 0.9 suggests growth is being underpriced. With a $10,030M market cap and Price/Sales of 0.8, investors are paying less than one times revenue for a healthcare operator that remains profitable at the EPS line, which is classic deep value with operational leverage embedded.

The Bear Case

The balance sheet is the obvious pressure point. Debt/Equity of 14.70% combined with an Altman Z-Score of 1.6 signals elevated financial risk, and the -114.70% operating margin is a glaring red flag that operational profitability is severely distorted. Return on Equity of just 3.10% is weak relative to the leverage employed, implying inefficient capital deployment. With no dividend, no yield support, and ambiguous sentiment metrics such as a 19.20% consensus rating and a 2.88 mean target price, investors are relying entirely on execution and multiple expansion while absorbing real solvency and margin risk.

Market Sentiment & Smart Money

Short Interest %

25.60%

Analyst Consensus

2.25

Average Analyst Price Target

$10.42

Institutional Ownership %

52.40%

1-Year Beta

1.46

Insider Buying % (6 Mo)

45.00%%

Distance to 52-Week High

28.70%%

Distance to 52-Week Low

100.90%%